

| | | | |
|------------|-------------|----------------------|-----------------------|
| Name | : Mr. DUMMY | Collected | : 11/7/2017 1:22:00PM |
| Lab No. | : 133434221 | Age: 25 Years | Gender: Male |
| A/c Status | : P | Ref By : Dr. UNKNWON | Report Status : Final |
| | | Received | : 11/7/2017 1:30:55PM |
| | | Reported | : 18/7/2017 3:39:24PM |

| Test Name | Results | Units | Bio. Ref. Interval |
|----------------|---|-------|--------------------|
| IHC MARKER(S) | RESULT | | |
| CYTOKERATIN 19 | Non-immunoreactive, score 0 in neoplastic cells | | |

SLIDE NO : B/ 2222222/17
 SPECIMEN : Biopsy for IHC markers.
 CLINICAL HISTORY : --
 GROSS : Received 1 formalin fixed paraffin embedded block labelled as 'ABCDE'
 IMPRESSION : **Features are consistent with XYZ**
 ADVISED : Clinical & radiological correlation.

INTERPRETATION

| RESULT | SCORE |
|---------------------------------|-------|
| Non immunoreactive | 0 |
| Immunoreactive in 1-25 % cells | 1+ |
| Immunoreactive in 26-50% cells | 2+ |
| Immunoreactive in 51-75% cells | 3+ |
| Immunoreactive in 76-100% cells | 4+ |

COMMENTS

Oct-2:- Oct-2 is a transcription factor belonging to the POU homeo-domain family and is a major regulator found in B lymphocytes. By binding to the octamer motif, Oct-2 promotes immunoglobulin transcription and regulates various lymphoid-specific genes. All tumor cell lines from the B-cell lineage, and a few from the T-cell lineage, express Oct-2. Oct-2 expression is significantly greater in Diffuse Large B-cell Lymphoma and Lymphocyte Predominant Hodgkin Lymphoma; therefore Oct-2 is a useful differential marker for these diseases.

NOTE

1. Detection system used is Polymer HRP
2. The impression is based on the material submitted and is not a complete surgical pathology report.
3. False negative IHC results due to inadequate fixation of the material sent for evaluation cannot be excluded.



| | | | |
|------------|-------------|----------------------|-----------------------|
| Name | : Mr. DUMMY | Collected | : 11/7/2017 1:22:00PM |
| Lab No. | : 133434221 | Age: 25 Years | Gender: Male |
| A/c Status | : P | Ref By : Dr. UNKNWON | Report Status : Final |
| | | Received | : 11/7/2017 1:30:55PM |
| | | Reported | : 18/7/2017 3:39:24PM |

| Test Name | Results | Units | Bio. Ref. Interval |
|------------------------------|---------|-------|--------------------|
| FIXATION REQUIREMENTS | | | |

- The volume of formalin fixative should be atleast 10 times the volume of the specimen.
- Decalcification solutions with strong acids should not be used.
- Specimens should be immersed in fixative within 1 hour of the biopsy/resection procedure (time of removal & time of immersion to be mentioned).
- In all resection (large) specimens, the tumour must be bisected prior to immersion in fixative

DR. HEMA MALINI AIYER
MD (PATH)
HOD-HISTOPATH/CYTOPATH

-----End of report-----

